Adaptive Non Current Liabilities Total from 2010 to 2024
| ADPT Stock | USD 5.94 0.21 3.66% |
Non Current Liabilities Total | First Reported 2018-12-31 | Previous Quarter 255.3 M | Current Value 247.3 M | Quarterly Volatility 133.3 M |
Check Adaptive Biotechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Adaptive Biotechnologies' main balance sheet or income statement drivers, such as Interest Income of 14.2 M, Discontinued Operations of 0.0 or Depreciation And Amortization of 13.1 M, as well as many indicators such as Price To Sales Ratio of 3.95, Dividend Yield of 0.0 or PTB Ratio of 2.41. Adaptive financial statements analysis is a perfect complement when working with Adaptive Biotechnologies Valuation or Volatility modules.
Adaptive | Non Current Liabilities Total |
Latest Adaptive Biotechnologies' Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of Adaptive Biotechnologies Corp over the last few years. It is Adaptive Biotechnologies' Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Adaptive Biotechnologies' overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
| Timeline |
Adaptive Non Current Liabilities Total Regression Statistics
| Arithmetic Mean | 443,804,533 | |
| Geometric Mean | 413,930,888 | |
| Coefficient Of Variation | 35.19 | |
| Mean Deviation | 147,010,027 | |
| Median | 566,102,000 | |
| Standard Deviation | 156,192,738 | |
| Sample Variance | 24396.2T | |
| Range | 362.6M | |
| R-Value | (0.84) | |
| Mean Square Error | 7826.2T | |
| R-Squared | 0.70 | |
| Significance | 0.000096 | |
| Slope | (29,265,193) | |
| Total Sum of Squares | 341546.4T |
Adaptive Non Current Liabilities Total History
About Adaptive Biotechnologies Financial Statements
Adaptive Biotechnologies shareholders use historical fundamental indicators, such as Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Although Adaptive Biotechnologies investors may analyze each financial statement separately, they are all interrelated. The changes in Adaptive Biotechnologies' assets and liabilities, for example, are also reflected in the revenues and expenses on on Adaptive Biotechnologies' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Total | 264.8 M | 276.3 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Adaptive Stock Analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.